Compare GSK plc (GSK) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Moody's Corporation — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Moody's Corporation trades at $464.23 (market cap $79.44B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Moody's Corporation for 132 Days on average.
| GSK | MCO | |
|---|---|---|
Market Cap | $91.88B | $79.44B |
Volume | 7,730,529 | 526,684 |
Sector | Health | Financials |
52-Week High | $61.18 | $539.61 |
52-Week Low | $43.24 | $412.23 |
Typical Hold Time | 93 Days | 132 Days |
Enterprise Value | $111.88B | $85.46B |
Dividend Yield | 3.9% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals. Revenue grew to $7.72B in 2025, with net income margin expanding to 34.25%. Recent news highlights Moody's top RiskTech100 ranking and expansion into Asia-Pacific via a PhilRatings stake. The stock faces resistance near $461, with support at $454.
Outlook remains positive given consistent earnings beats, high profitability, and a $536.40 analyst price target implying 17% upside. Risks include high valuation multiples and macroeconomic sensitivity. Institutional sentiment is bullish with 56% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
